Last reviewed 2026-04-19 · How we verify

CAMAZEPAM

Phase 2 active Small molecule

CAMAZEPAM is a camazepam drug. It is currently in Phase 2 development.

Camazepam works by enhancing the activity of a neurotransmitter called GABA, which helps to calm the brain and reduce anxiety.

Camazepam is a small molecule belonging to the drug class of camazepam. It is a benzodiazepine derivative, but its exact target and mechanism of action are unknown. Camazepam is used to treat anxiety and insomnia, although its commercial status and approved indications are unclear. As a camazepam, it is likely to have sedative and anxiolytic effects, but further research is needed to confirm its efficacy and safety. Its pharmacokinetic properties, such as half-life and bioavailability, are also unknown.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CAMAZEPAM
Drug class	camazepam
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is like a busy city with lots of people talking and moving around. GABA is like a traffic cop that helps to slow down the traffic and keep everything calm. Camazepam helps the traffic cop to do its job more effectively, which can help to reduce anxiety and promote relaxation.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CAMAZEPAM CI brief — competitive landscape report
CAMAZEPAM updates RSS · CI watch RSS

Frequently asked questions about CAMAZEPAM

What is CAMAZEPAM?

CAMAZEPAM is a camazepam drug.

How does CAMAZEPAM work?

Camazepam works by enhancing the activity of a neurotransmitter called GABA, which helps to calm the brain and reduce anxiety.

What drug class is CAMAZEPAM in?

CAMAZEPAM belongs to the camazepam class. See all camazepam drugs at /class/camazepam.

What development phase is CAMAZEPAM in?

CAMAZEPAM is in Phase 2.

Drug class: All camazepam drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing